ALNY AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.
ALNY Current Performance
-1.28%
Alnylam pharmaceuticals, inc.
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ALNY
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
IONS | Ionis pharmaceuticals inc | 3 | 5 | 5 | 2 | 1 | |
ADPT | Adaptive biotechnologies corp | 4 | 5 | 2 | 1 | 1 | |
ALIM | Alimera sciences, incorporation | 3 | 5 | 3 | 2 | 1 | |
BPMC | Blueprint medicines corp | 4 | 4 | 2 | 3 | 1 | |
AGIO | Agios pharmaceuticals inc | 2 | 5 | 5 | 3 | 1 |
- IONS Ionis pharmaceuticals incValue 3Trend 5Swing Trading 5Whale Interest 2Dividend 1See more
ALNY Profile
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company's lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.